Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced the lodgement of an international patent application aimed at protecting the use of Veyonda (idronoxil) in blocking the development of septic shock associated with infections. …
New data moves Noxopharm to protect Veyonda in septic shock treatment
April 6, 2021 Australian Biotech
Latest Video
New Stories
-
If coercion and retribution are bad for supermarket customers, they must be bad for patients
April 18, 2024 - - Latest News -
AbbVie announces the appointment of new Australia-NZ human resources director
April 18, 2024 - - BioPharma -
'Under Karen’s leadership our local business has thrived both commercially and culturally'
April 18, 2024 - - Latest News -
Retail leader's surprise at the size of revenue revealed by Chemist Warehouse
April 17, 2024 - - Latest News -
Longstanding health sector leader and advocate steps down after 24 years
April 17, 2024 - - Latest News -
'We celebrate our 60th anniversary in Australia, I am extremely optimistic about the next 60'
April 17, 2024 - - Latest News -
Ex-AusBiotech CEO appointed to lead peak body for manufacturing technology sector
April 16, 2024 - - Latest News